{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:17:16Z","timestamp":1791145036340,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejps.2016.08.015","type":"journal-article","created":{"date-parts":[[2016,8,7]],"date-time":"2016-08-07T12:18:32Z","timestamp":1470572312000},"page":"274-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["HER2-targeted antibody drug conjugates for ovarian cancer therapy"],"prefix":"10.1016","volume":"93","author":[{"given":"Jing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihou","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejps.2016.08.015_bb0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12282-015-0587-x","article-title":"HER2-directed therapy: current treatment options for HER2-positive breast cancer","volume":"22","author":"Ahmed","year":"2015","journal-title":"Breast Cancer"},{"issue":"17","key":"10.1016\/j.ejps.2016.08.015_bb0010","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.ejps.2016.08.015_bb0015","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1038\/sj.emboj.7601191","article-title":"Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation","volume":"25","author":"Anido","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.ejps.2016.08.015_bb0020","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2119\/molmed.2012.00302","article-title":"Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer","volume":"18","author":"Barginear","year":"2012","journal-title":"Mol. Med."},{"issue":"23","key":"10.1016\/j.ejps.2016.08.015_bb0025","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1002\/cncr.27622","article-title":"A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer","volume":"118","author":"Beeram","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejps.2016.08.015_bb0030","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.humpath.2013.11.016","article-title":"HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer","volume":"45","author":"Chao","year":"2014","journal-title":"Hum. Pathol."},{"issue":"4","key":"10.1016\/j.ejps.2016.08.015_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061565","article-title":"HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer","volume":"8","author":"Chay","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ejps.2016.08.015_bb0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.ejps.2016.08.015_bb0045","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1021\/bc800289a","article-title":"Novel peptide linkers for highly potent antibody-auristatin conjugate","volume":"19","author":"Doronina","year":"2008","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.ejps.2016.08.015_bb0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.canlet.2014.08.026","article-title":"Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine","volume":"354","author":"Drinberg","year":"2014","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.ejps.2016.08.015_bb0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies","volume":"21","author":"Ducry","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"13","key":"10.1016\/j.ejps.2016.08.015_bb0060","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-10-2461","article-title":"Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies","volume":"17","author":"Faratian","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ejps.2016.08.015_bb0065","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2011.10.022","article-title":"A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"124","author":"Garcia","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ejps.2016.08.015_bb0070","first-page":"122","article-title":"HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches","volume":"2","author":"Garrido-Castro","year":"2013","journal-title":"Transl. Lung Cancer Res."},{"issue":"26","key":"10.1016\/j.ejps.2016.08.015_bb0075","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2005.05.4221","article-title":"Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status","volume":"24","author":"Gordon","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ejps.2016.08.015_bb0080","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.ejps.2016.08.015_bb0085","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2016.08.015_bb0090","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"10.1016\/j.ejps.2016.08.015_bb0095","first-page":"2227","article-title":"Microtubule inhibitor-based antibody-drug conjugates for cancer therapy","volume":"7","author":"Klute","year":"2014","journal-title":"Onco. Targets Ther."},{"issue":"10","key":"10.1016\/j.ejps.2016.08.015_bb0100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1586\/14737140.2013.846830","article-title":"HER2 and lung cancer","volume":"13","author":"Landi","year":"2013","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"22","key":"10.1016\/j.ejps.2016.08.015_bb0105","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejps.2016.08.015_bb0110","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ejps.2016.08.015_bb0115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/CCO.0b013e32834b895c","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review","volume":"23","author":"Mathew","year":"2011","journal-title":"Curr. Opin. Oncol."},{"issue":"16","key":"10.1016\/j.ejps.2016.08.015_bb0120","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazieres","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2016.08.015_bb0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejps.2016.08.015_bb0130","first-page":"743193","article-title":"The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy","volume":"2012","author":"Mitri","year":"2012","journal-title":"Chemother. Res. Pract."},{"issue":"12","key":"10.1016\/j.ejps.2016.08.015_bb0135","first-page":"4744","article-title":"Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina","year":"2001","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejps.2016.08.015_bb0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrd4009","article-title":"Maturing antibody-drug conjugate pipeline hits 30","volume":"12","author":"Mullard","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejps.2016.08.015_bb0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/1535-7163.MCT-06-0401","article-title":"Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling","volume":"6","author":"Mullen","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.ejps.2016.08.015_bb0150","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ejps.2016.08.015_bb0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/bcr327","article-title":"Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2\/HER-2 and family members","volume":"3","author":"Olayioye","year":"2001","journal-title":"Breast Cancer Res."},{"issue":"7","key":"10.1016\/j.ejps.2016.08.015_bb0160","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody-drug conjugates: current status and future directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.ejps.2016.08.015_bb0165","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2016.08.015_bb0170","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3816\/COC.2008.n.005","article-title":"HER2 overexpression\/amplification and trastuzumab treatment in advanced ovarian cancer: a GINECO phase II study","volume":"1","author":"Ray-Coquard","year":"2008","journal-title":"Clinical Ovarian Cancer"},{"issue":"2 Pt 1","key":"10.1016\/j.ejps.2016.08.015_bb0175","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/1078-0432.843.11.2","article-title":"In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate","volume":"11","author":"Sanderson","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ejps.2016.08.015_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098528","article-title":"HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression","volume":"9","author":"Seo","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejps.2016.08.015_bb0185","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bjc.2011.62","article-title":"The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer","volume":"104","author":"Sheng","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.ejps.2016.08.015_bb0190","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/bjc.2012.176","article-title":"Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer","volume":"106","author":"Sims","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejps.2016.08.015_bb0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000356201","article-title":"HER2 expression and PI3K-Akt pathway alterations in gastric cancer","volume":"89","author":"Sukawa","year":"2014","journal-title":"Digestion"},{"issue":"7","key":"10.1016\/j.ejps.2016.08.015_bb0200","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1245\/s10434-011-1554-1","article-title":"Her-2\/neu gene amplification in esophageal adenocarcinoma and its influence on survival","volume":"18","author":"Thompson","year":"2011","journal-title":"Ann. Surg. Oncol."},{"issue":"20","key":"10.1016\/j.ejps.2016.08.015_bb0205","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1111\/j.1742-4658.2008.06625.x","article-title":"Differential binding of human immunoagents and Herceptin to the ErbB2 receptor","volume":"275","author":"Troise","year":"2008","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.ejps.2016.08.015_bb0210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2011.03.030","article-title":"Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory\/resistant ovarian and primary peritoneal carcinoma","volume":"122","author":"Weroha","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ejps.2016.08.015_bb0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-015-3503-3","article-title":"A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity","volume":"153","author":"Yao","year":"2015","journal-title":"Breast Cancer Res. Treat."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716303049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716303049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T05:34:41Z","timestamp":1656999281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098716303049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":43,"alternative-id":["S0928098716303049"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2016.08.015","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2-targeted antibody drug conjugates for ovarian cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2016.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}